| Literature DB >> 31482986 |
Ronaldo Campos Rodrigues1, Katia Martins Lopes de Azevedo1, Samuel Datum Moscavitch1, Sergio Setubal1, Claudio Tinoco Mesquita1.
Abstract
BACKGROUND: Most cardiovascular abnormalities in patients infected with the human immunodeficiency virus (HIV) have been associated with myocardial damage directly caused by the virus. Some cases, however, may be associated with adverse effects from antiretroviral therapy (ART). New ventricular function assessment techniques are capable of detecting early changes in the cardiac function of HIV-infected patients using or not using ART. The usefulness of these techniques has been little employed in these patients.Entities:
Mesh:
Year: 2019 PMID: 31482986 PMCID: PMC7020862 DOI: 10.5935/abc.20190169
Source DB: PubMed Journal: Arq Bras Cardiol ISSN: 0066-782X Impact factor: 2.000
Figure 1Apical four-chamber – percentage of longitudinal strain in the basal, middle and apical segments of the inferior and anterolateral septal walls.
Figure 2Apical three-chamber – percentage of longitudinal strain in the basal, middle and apical segments of the inferolateral and anterior septal walls.
Figure 3Apical two-chamber – percentage of longitudinal strain in the basal, middle and apical segments of the inferior and anterior walls.
Demographic, clinical and laboratory variables according to the group
| Variable | NT (n = 11) | PI (n = 24) | NNRTI (n = 33) | Control (n = 30) | Kruskal-Wallis test (p) | |
|---|---|---|---|---|---|---|
| Age (years) | M ± DP | 33.3 ± 4.1 | 44.8 ± 8.7 | 39.4 ± 8.0 | 49.9 ± 11.6 | < 0.001 |
| Md ± IQR | 33.0 ± 3.0 | 43.0 ± 10.5 | 39.0 ± 8.0 | 48.5 ± 15.0 | ||
| Gender | Male | 9 (81.8%) | 15 (62.5%) | 14 (42.4%) | 22 (73.3%) | 0.033 (chi-square) |
| Female | 2 (18.2%) | 9 (37.5%) | 19 (57.6%) | 8 (26.7%) | ||
| Md ± IQR | ||||||
| Heart rate (bpm) | M ± SD | 75.6 ± 7.3 | 72.0 ± 8.9 | 78.1 ± 6.2 | 73.2 ± 6.1 | 0.029 |
| Md ± IQR | 78.0 ± 14.0 | 73.5 ± 16.0 | 77.0 ± 9.5 | 75.0 ± 8.8 | ||
| SBP (mmHg) | M ± SD | 121.4 ± 6.0 | 129.3 ± 6.8 | 129.1 ± 6.8 | 123.8 ± 5.5 | 0.001 |
| Md ± IQR | 120.0 ± 5.0 | 130.0 ± 10.0 | 130.0 ± 5.0 | 125.0 ± 10.0 | ||
| DBP (mmHg) | M ± SD | 71.4 ± 4.5 | 70.0 ± 7.7 | 70.3 ± 7.5 | 67.8 ± 5.7 | 0.338 |
| Md ± IQR | 70.0 ± 5.0 | 70.0 ± 20.0 | 70.0 ± 15.0 | 70.0 ± 5.0 | ||
| Blood glucose (mg/dl) | M ± SD | 84.8 ± 14.2 | 79.7 ± 11.2 | 83.0 ± 9.5 | 82.4 ± 5.7 | 0.455 |
| Md ± IQR | 82.0 ± 23.0 | 79.0 ± 9.0 | 81.0 ± 13.5 | 81.0 ± 7.0 | ||
| Total cholesterol (mg/dL) | M ± SD | 164.6 ± 26.8 | 189.0 ± 56.3 | 183.9 ± 30.0 | 196.3 ± 17.4 | 0.021 |
| Md ± IQR | 163.0 ± 40.0 | 198.0 ± 54.0 | 181.0 ± 42.0 | 199.0 ± 26.0 | ||
| LDL-c (mg/dL) | M ± SD | 102.6 ± 27.6 | 108.7 ± 48.5 | 110.0 ± 27.9 | 118.9 ± 18.5 | 0.229 |
| Md ± IQR | 104.0 ± 49.0 | 109.0 ± 66.0 | 102.0 ± 36.0 | 122.0 ± 27.0 | ||
| HDL-c (mg/dL) | M ± SD | 47.5 ± 16.7 | 42.6 ± 17.5 | 55.0 ± 16.0 | 53.4 ± 3.5 | 0.007 |
| Md ± IQR | 43.0 ± 30.0 | 41.0 ± 22.0 | 52.0 ± 18.0 | 54.0 ± 4.0 | ||
| Triglycerides (mg/dL) | M ± SD | 101.1 ± 39.1 | 174.8 ± 78.2 | 119.7 ± 115.2 | 127.0 ± 15.5 | < 0.001 |
| Md ± IQR | 86.0 ± 79.0 | 165.0 ± 106.0 | 87.0 ± 71.0 | 123.5 ± 27.0 | ||
| CD4+ lymphocytes/mm3 | M ± SD | 502.5 ± 206.3 | 534.4 ± 323.1 | 693.2 ± 317.7 | - | 0.044 |
| Md ± IQR | 426.0 ± 310.0 | 404.0 ± 436.0 | 644.0 ± 297.0 | - |
M: mean; SD: standard deviation; Md: median; IQR: interquartile range; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; NT: HIV-positive patients not using antiretroviral therapy. PI: HIV-positive patients on protease inhibitor therapy. NNRTI: HIV-positive patients on non-nucleoside reverse transcriptase inhibitor therapy. Control: healthy HIV-negative individuals.
Echocardiographic variables
| Variable | NT (n = 11) | PI (n = 24) | NNRTI (n = 33) | Control (n = 30) | Kruskal-Wallis test (p) | |
|---|---|---|---|---|---|---|
| Aorta (mm) | M ± SD | 28.27 ± 1.85 | 30.58 ± 3.02 | 28.73 ± 2.97 | 29.53 ± 2.08 | 0.026 |
| Md ± IQR | 29.00 ± 3.00 | 30.00 ± 3.50 | 29.00 ± 4.00 | 30.00 ± 2.00 | ||
| LA diameter (mm) | M ± SD | 31.18 ± 3.82 | 33.21 ± 3.22 | 31.64 ± 4.59 | 34.33 ± 2.55 | 0.004 |
| Md ± IQR | 30.00 ± 6.00 | 32.00 ± 4.50 | 31.00 ± 3.00 | 34.00 ± 4.00 | ||
| LVDd-i (mm/m2) | M ± SD | 29.75 ± 0.79 | 29.75 ± 1.81 | 28.67 ± 2.36 | 28.20 ± 1.73 | 0.020 |
| Md ± IQR | 29.70 ± 1.13 | 29.87 ± 2.75 | 29.73 ± 4.22 | 28.65 ± 2.84 | ||
| LVSD (mm) | M ± SD | 30.36 ± 2.38 | 31.17 ± 4.04 | 32.18 ± 3.26 | 32.17 ± 2.78 | 0.248 |
| Md ± IQR | 30.00 ± 5.00 | 31.00 ± 7.00 | 32.00 ± 4.00 | 31.50 ± 4.00 | ||
| IVS (mm) | M ± SD | 7.18 ± 0.98 | 7.88 ± 1.08 | 7.91 ± 0.95 | 9.03 ± 0.76 | < 0.001 |
| Md ± IQR | 7.00 ± 2.00 | 8.00 ± 2.00 | 8.00 ± 2.00 | 9.00 ± 2.00 | ||
| PP (mm) | M ± SD | 7.00 ± 1.00 | 7.42 ± 1.18 | 7.67 ± 0.92 | 8.33 ± 0.80 | < 0.001 |
| Md ± IQR | 7.00 ± 0.00 | 8.00 ± 1.00 | 8.00 ± 1.00 | 9.00 ± 1.00 | ||
| LVEF – Simpson (%) | M ± SD | 66.64 ± 3.83 | 62.46 ± 3.60 | 63.55 ± 4.10 | 64.17 ± 3.50 | 0.030 |
| Md ± IQR | 67.00 ± 5.00 | 62.00 ± 5.00 | 63.00 ± 6.00 | 64.00 ± 6.00 | ||
| LV mass index (g/m2) | M ± SD | 82.23 ± 16.76 | 104.49 ± 24.01 | 90.01 ± 19.54 | 108.12 ± 14.25 | < 0.001 |
| Md ± IQR | 82.28 ± 13.59 | 106.35 ± 37.69 | 89.34 ± 26.89 | 110.61 ± 18.10 | ||
| E/A ratio | M ± SD | 1.46 ± 0.40 | 1.33 ± 0.34 | 1.52 ± 0.41 | 1.18 ± 0.07 | < 0.001 |
| Md ± IQR | 1.34 ± 0.38 | 1.30 ± 0.22 | 1.50 ± 0.44 | 1.18 ± 0.09 | ||
| E’ septal annulus (cm/s) | M ± SD | 9.55 ± 1.87 | 9.03 ± 1.91 | 10.54 ± 2.21 | 8.38 ± 0.41 | < 0.001 |
| Md ± IQR | 9.00 ± 1.90 | 8.35 ± 2.00 | 10.00 ± 3.00 | 8.15 ± 0.60 | ||
| S’ septal annulus (cm/s) | M ± SD | 8.25 ± 1.09 | 8.10 ± 0.68 | 8.49 ± 1.41 | 9.03 ± 0.95 | 0.001 |
| Md ± IQR | 8.00 ± 2.00 | 8.00 ± 0.40 | 8.10 ± 1.00 | 8.80 ± 0.60 | ||
| E/E’ ratio | M ± SD | 8.41 ± 1.33 | 8.72 ± 2.03 | 7.08 ± 1.65 | 9.29 ± 0.62 | < 0.001 |
| Md ± IQR | 8.40 ± 2.59 | 9.08 ± 3.04 | 7.27 ± 2.45 | 9.38 ± 0.88 | ||
| LA volume index (ml/m²) | M ± SD | 30.38 ± 6.16 | 29.93 ± 4.76 | 29.48 ± 5.60 | 29.56 ± 1.81 | 0.839 |
| Md ± IQR | 29.11 ± 1.09 | 30.40 ± 3.48 | 29.17 ± 7.32 | 29.88 ± 2.76 | ||
| S lateral tricuspid annulus (cm/s) | M ± SD | 11.29 ± 1.54 | 10.87 ± 1.42 | 12.23 ± 1.90 | 11.49 ± 0.90 | 0.014 |
| Md ± IQR | 11.00 ± 2.00 | 10.80 ± 2.00 | 12.00 ± 2.00 | 11.70 ± 0.50 |
M: mean; SD: standard deviation; Md: median; IQR: interquartile range; ST: HIV+ patient not using antiretroviral therapy. PI: HIV-positive patients on protease inhibitor therapy; NNRTI: HIV-positive patients on non-nucleoside reverse transcriptase inhibitor therapy. LVDD: left ventricular diastolic diameter; LVSD: left ventricular systolic diameter; ΔD%: left ventricle; LA: left atrium
Behavior of global longitudinal strain according to the group
| Variable | NT (n = 11) | PI (n = 24) | NNRTI (n = 33) | Control (n = 30) | Kruskal-Wallis test (p) | |
|---|---|---|---|---|---|---|
| Global longitudinal strain | M ± SD | -18.11 ± 1.28 | -17.96 ± 4.89 | -18.15 ± 3.07 | -20.66 ± 0.79 | 0.001 |
| Md ± IQR | -17.70 ± 2.07 | -18.27 ± 6.14 | -18.47 ± 4.27 | -20.77 ± 1.00 |
M: mean; SD: standard deviation; Md: median; IQR: interquartile range.